Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

Antiobesity medications tirzepatide and semaglutide offer long-term health benefits but are not cost-effective.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

US pharmaceutical giant Eli Lilly has launched its blockbuster diabetes and weight-loss drug, Mounjaro, in India following ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Lexaria Bioscience (LEXX) announced pharmacokinetic results from Human Study #3 or GLP-1-H24-3, comparing an oral version of ...